Biomedical subjects

B Sádaba

Publications and source records attributed to B Sádaba.

17 recordsLinked to original sources

PubMed1999

Rapid high-performance liquid chromatographic determination of cefepime in human plasma.

A simple, rapid and reproducible high-performance liquid chromatographic method for the quantitative determination of cefepime in human plasma was developed. Ceftazidime was used as internal standard. Chromatography was performed on a reversed-phase encapped column (Hypersil BDS C18). The samples, after protein precipitation, were eluted with a mobile phase of acetonitrile-acetate buffer, pH 4 (2.8:97.2, v/v). The detection wavelength was 254 nm. The limit of quantitation of cefepime was 0.5 microgram/mL and only 0.5 mL of plasma sample was required for the determination. The average cefepime recoveries over a concentration range of 0.5-500 micrograms/mL ranged from 98 to 104%. Precision and accuracy did not exceed 5%.

Cefepime↗

PubMed1999

[Sequential treatment with fluoroquinolones].

Explore the source record for details and available documents.

Anti-Infective Agents↗

PubMed1998

Concurrent clarithromycin and cyclosporin A treatment.

Although macrolides have been associated with significant pharmacokinetic interactions, clarithromycin is considered to have a low interaction capacity. In this study, six transplant recipients treated with cyclosporin A also received clarithromycin. In all patients, the dose of cyclosporin A had to be reduced by a mean of 33% per day depending on the macrolide dose. Normalization of the dosage parameters began on the fourth day after stopping clarithromycin treatment. Co-administration of cyclosporin A and clarithromycin may lead to increases in whole blood cyclosporin levels, and appropriate dose reductions should be considered.

Anti-Bacterial Agents↗

PubMed1997

[Clinical pharmacology and indications of meropenem in severe pediatric infection].

The choice of an antibiotic for the treatment of a serious paediatric infection is generally a difficult problem. The arrival of Carbapenem resulted an important advance in the field of medicine due to its broad-spectrum, low incidence of resistances and good safety profile. Among Carbapenems, Meropenem introduction represents a progress because of its pharmacokinetics characteristics and blood-brain barrier penetration. Meropenem dosage depends on the patient weight, and the way of administration is potentially easier. Meropenem has been compared with the most used paediatric antimicrobial in controlled and randomised clinical trials, showing a high efficacy in the treatment of several infections (respiratory, urinary, intraabdominal, dermatological, septicemia) and in neutropenic and cystic fibrosis patients aged between one month and twelve years old. Meropenem is specially useful in the bacterial meningitis treatment because it penetrates into the cerebrospinal fluid of patients with inflamed meninges and reaches therapeutic concentrations, and because appearance of seizures is low. Adverse reactions produced by Meropenem show a poor incidence and its severity is usually mild. With regard to this characteristics, it can be concluded that Meropenem is an antimicrobial which efficacy and safety profiles guarantee its use in the treatment of severe paediatric infections.

Bacterial Infections↗

PubMed1997